Autoverification without the anxiety
How clinical labs design autoverification: rule families, QC gating, validation, and exception queues — so automatic release stays defensible for supervisors and QA.
- autoverification
- lab middleware
- quality control
- delta check
- clinical laboratory
- laboratory supervisor
- LIS
Definition
Autoverification (AV) is the process of accepting or rejecting laboratory results for automatic delivery using a predetermined set of criteria, applied as data flows from instrument through middleware (and/or LIS) to a reportable result.
It is laboratory-owned policy, not “auto-approve everything,” not a replacement for judgment on exceptions, and not a set-and-forget switch.
Industry guidance (including CLSI-oriented frameworks such as AUTO10 / AUTO15 for AV design and EP33 for delta checks) stresses the same point: design, validate, and monitor algorithms for your methods and populations — do not blindly import a vendor default pack.
Audience: lab supervisors / QA and informatics teams worldwide.
Why labs want AV (when it is done right)
- Turnaround — routine results leave without waiting in a manual queue
- Focus — technologists spend time on flags, deltas, criticals, and odd panels
- Consistency — the same rules fire the same way every shift
- Scale — volume can grow without a 1:1 increase in review headcount
Labs that regret AV usually failed at ownership, validation, or exception design — not at “turning it on.”
Building blocks of a trustworthy ruleset
1. Instrument and sample integrity flags
Hemolysis, icterus, lipemia, clot, aspiration errors, dilution flags — anything that says the number is not yet trustworthy.
2. Analytic / sanity limits
Hold results outside method performance or clinically plausible bounds.
3. Critical / alert values
AV may detect criticals; the lab’s defined alert path still owns notification. Criticals should not quietly chart without that process.
4. Delta checks
Compare to a recent prior for the same patient. Large swings may be true change — or wrong sample / analytic glitch. Choose assays and investigation paths deliberately (EP33-style thinking).
5. Consistency / cross-analyte checks
Related tests that should not disagree without a story (discipline-specific).
6. Quality control as a gate
If QC for an assay is failed or overdue, patient AV for that assay should stop. See QC that doesn’t live in a spreadsheet.
Pass applicable checks → auto-release. Fail any → review queue with context.
Where anxiety usually comes from
| Fear | Often caused by | Fix |
|---|---|---|
| Releases something dangerous | Rules too wide; criticals/QC not gated | Tighten; hard-stop on criticals and failed QC |
| Drown in holds | Rules too narrow; noisy deltas | Tune with real data; improve exception UX |
| Nobody owns the rules | Vendor defaults, no versioning | Lab ownership, change control, audit trail |
| Can’t prove it works | No validation plan | Edge cases + parallel review |
| Techs ignore the queue | Vague holds | Show which rule fired and next action |
Validation (non-negotiable)
- Define policy with lab leadership — what may auto-release, what must never
- Encode rules with versioning — who changed what, when
- Technical validation — limits, deltas, flags, QC fail, criticals
- Parallel / phased go-live — compare to expert review; measure hold rate and escapes
- Ongoing monitors — hold rate by assay, time-in-queue, rule hits, QC-related stops
If you cannot explain a rule and show how you tested it, you have hope — not AV.
Also document pause / resume before go-live: When to pause autoverification.
What “good” looks like on a busy shift
The exception queue shows patient/specimen IDs, result and flags, which rule held it, priors when relevant, and a clear next action (rerun, dilute, call, release with comment).
FAQ
Is autoverification safe?
Yes when rules are lab-owned, validated, monitored, and gated by critical-value and QC policy. It is unsafe when defaults are imported without validation or when failed QC still allows patient release.
Does AV replace technologists?
No. It filters routine releases so judgment goes to exceptions.
Should rules live in the LIS or in middleware?
Either can host rules. Multi-vendor labs often prefer middleware so AV and QC gating stay consistent across analyzers before the LIS. See What lab middleware actually does.
Related reading
- Encode QC gates and autoverification you can defend
- Audit-ready trails for lab middleware
- What lab middleware actually does
About TransLABtor
TransLABtor applies operational and AV rules in the analyzer–LIS middle layer, with QC gating on the same path and exception context for review. The LIS remains the system of record. Book a demo or browse interfaces.